Condition
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma clinical trials that are recruiting, at sites in 3 countries (most in China (3), Poland (1), Switzerland (1)). By phase: Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 3Countries
Newest Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CD38-targeted PET/CT for detecting Multiple Myeloma lesions compared with FDG PET/CT | — | Guilin, Guangxi | Recruiting | Aug 24, 2026 |
| Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors | Phase 1/2 | Beijing, Beijing Municipality | Recruiting | Feb 13, 2026 |
| Geriatric assessment before CAR‑T or bispecific antibody therapy to predict side effects and outcomes in older adults | — | Bern and 1 other locations | Recruiting | Dec 30, 2025 |
| AI-assisted health education for people with blood cancers | — | Wuhan, Hubei | Recruiting | Dec 26, 2025 |
| Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers | — | Gdansk, Pomeranian Voivodeship | Recruiting | Dec 8, 2025 |
All recruiting trials (5)
-
CD38-targeted PET/CT for detecting Multiple Myeloma lesions compared with FDG PET/CT
This study tests a CD38-targeted PET/CT scan to see if it detects multiple myeloma lesions as well or better than the standard FDG PET/CT.
-
Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors
This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.
-
Geriatric assessment before CAR‑T or bispecific antibody therapy to predict side effects and outcomes in older adults
This study will test whether a brief geriatric assessment done before CAR‑T or bispecific antibody treatment can help predict side effects and outcomes for people aged 65 and older with aggressive lymphoma or multiple myeloma.
-
AI-assisted health education for people with blood cancers
This project tests whether an AI chatbot can improve awareness of clinical trials and willingness to join among adults with blood cancers.
-
Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers
This trial will test whether reduced‑dose apixaban or rivaroxaban pills can prevent blood clots as well and as safely as daily low‑molecular‑weight heparin injections in people with hematologic malignancies.
Related topics
Quick answers
How many Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (3 trials), Poland (1 trial), Switzerland (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.